708274-24-2

Upstream product

• 368-83-2 3-(trifluoromethyl)benzaldehyde oxime 
• 69053-93-6 α-chloro-(3-trifluoromethylbenzaldehyde)oxime 
• 454-89-7 3-Trifluoromethylbenzaldehyde 
• 708274-23-1 methyl 3-[3-(trifluoromethyl)phenyl]-4,5-dihydroisoxazole-5-carboxylate 

Downstream Products

• 857651-07-1 tert-butyl [(3S)-1-(3-[3-(trifluoromethyl)phenyl]-4,5-dihydroisoxazol-5-ylcarbonyl)pyrrolidin-3-yl]carbamate 
• 1174749-33-7 N-[3-(4-{4-(3-(3-trifluoromethyl-phenyl)-4,5-dihydro-isoxazole-5-carbonyl)-piperazin-1-yl}-3-fluoro-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide 
• 1394830-06-8 (3S)-1-(3-[3-(trifluoromethyl)phenyl]-4,5-dihydroisoxazol-5-ylcarbonyl)-pyrrolidin-3-amine hydrochloride 

Relevant academic research and scientific papers

A METHOD OF TREATING LIVER FIBROSIS

The present invention relates to a method of treating hepatis C and/or liver fibroisis with 3-cycloalkylaminopyrrolidine derivatives of the present invention

Synthesis and antibacterial evaluation of isoxazolinyl oxazolidinones: Search for potent antibacterial

A series of (5S) N-(3-{3-fluoro-4-[4-(3-aryl-4,5-dihydro-isoxazole-5-carbonyl)-piperazin-1-yl]-phenyl}-2-oxo-oxazolidin-5-ylmethyl)-acetamide(6a-o) were synthesized and their in vitro antibacterial activity against various resistant Gram-positive and Gram-negative bacteria were evaluated. Most of the synthesized compounds showed 2 to 10 fold lower MIC values compared to linezolid against Staphylococcus aureus ATCC 25923, ATCC 70069, ATCC 29213, Bacillus cereus MTCC 430, Enterococcus faecalis MTCC439, Klebsiella pneumoniae ATCC 27736, and Streptococcus pyogens.

3-Cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors

The present invention relates to 3-cycloalkylaminopyrrolidine derivatives of the formula I: (wherein R1, R2, R3, R4, R5, R6, R7, X, Y and Z are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as modulators of the CCR2 and/or CCR5 receptor. The compounds and compositions of the invention may bind to chemokine receptors, e.g., the CCR2 and/or CCR5 chemokine receptors, and are useful for treating diseases associated with chemokine, e.g., CCR2 and/or CCR5, activity, such as atherosclerosis, restenosis, lupus, organ transplant rejection and rheumatoid arthritis.

Isoxazoline derivatives and plant growth regulators

Novel 3-substituted phenyl-2-isoxazoline-5-carboxylic acids or esters thereof. These compounds have excellent properties as plant growth regulators.